Announced
Completed
Financials
Tags
Venture Capital
Cross Border
Canada
Biotechnology
Private
Completed
Single Bidder
clinical stage biotechnology
Acquisition
Private Equity
Minority
Friendly
Synopsis
New Enterprise Associates, a venture capital firm, led a $70m series C round in Inversago Pharma, a clinical stage biotech company, with participation from Forbion, Amgen, Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations. “We are privileged to have the support and commitment of such an impressive investor syndicate at this critical stage of the Company’s development. This new round of financing is a strong endorsement of the whole Inversago team, who have carried the vision to leverage the potential of the CB1 blockade in developing potent treatments for a growing number of patients suffering from metabolic conditions, such as Diabetic Kidney Diseases and other diabetes-related condition,” François Ravenelle, Inversago Pharma CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.